Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2314 PWToday Stories


07 May 14

UK-based contract research organisation Onyx Scientific has completed a development and API manufacturing project with US-based Neuronascent, Inc to support the company with its focus on neurologic disorders.

Neuronascent develops orally available, novel neurogenic and neurorestorative therapeutics that target Parkinson’s disease, Down syndrome, Alzheimer’s disease and post-traumatic stress disorder.

Onyx Scientific assisted the Maryland headquartered firm with the process development and production of a 1kg batch of API that was used in the pre-IND submission along with supporting with initial stability data.

Neuronascent’s lead candidate is NNI-362, which is aimed at Alzheimer’s and Parkinson’s disease and other neurodegenerative disorders.

Judith Kelleher-Andersson, Ph.D., founder, president and chief executive officer at Neuronascent said: “Onyx Scientific has the ability to synthesize high quality API, while still taking into account the time and financial concerns of a small biotech company.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.